Diaceutics signs five-year deal with BioReference Laboratories
24 April 2017 | 0
Dundalk-based data insights and solutions company Diaceutics, has secured a five-year multi-million-euro partnership with BioReference Laboratories. The exclusive partnership will see Diaceutics acquire real-time testing data from the US company, allowing it to help pharmaceutical companies achieve faster rollouts of new drugs.
Through its partnership with BioReference, which works with 30,000 healthcare providers across the US, Diaceutics will have access to data from 50,000 patient samples per day. Coupled with insights from BioReference, the real-time data will help improve patient testing by ensuring that pharmaceutical companies better understand the testing patterns of physicians considering precision medicine therapies for patients.
Diaceutics will integrate the data gathered from BioReference with its existing lab data accumulated through partnerships with other labs. Together, the data will allow Diaceutics to provide pharma with more complete, aggregated testing data that meets their very specific requirements – helping them to close the 20% patient gap in the oncology testing market and achieve a better return on new drug investments.
“Diagnostic data from laboratories like BioReference helps pharmaceutical companies better understand the testing journey that patients go on in the often difficult search for a targeted therapy,” said Peter Keeling, CEO, Diaceutics. “That information allows pharma to pinpoint patients that need to be on a specific – and often life-changing – drug, accelerate speed to market for new drugs and improve patient outcomes.
“Timing is key for many patients Diaceutics strives to increase the number of patients correctly tested, therefore increasing the demand for new drugs – an attractive prospect for pharmaceutical companies – and ultimately significantly improving patient outcomes.
“We have seen first-hand the improved decision making by our pharma clients when presented with the relevant data trends in specific disease areas. Enriching our real time and retrospective analytics with BioReference’s knowledgebase allows us to further map the diagnostic journey of patients and help pharmaceutical companies better understand how testing impacts precision prescribing.
“With this information, we can simply enable better decision making and investment in patient, physician and laboratory education.”
Richard Faherty, executive vice president, BioReference, said: “With knowledge derived from more than 85 million patient samples and relationships with more than 30,000 healthcare providers, we have developed unique insights that can help pharmaceutical companies provide targeted therapies to patients that help fulfil the vision of precision medicine.
“Diaceutics is transforming patient testing and has built trusted relationships with pharmaceutical companies by providing years of expert analysis to support drug launches. We are delighted to be able to work closely with them to meet the needs of our mutual customers and patients around the world seeking more effective therapies.”